OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

Clinical trial NCT06182696 · RECRUITING

Trial details

NCT number: NCT06182696
Sponsor: OriCell Therapeutics Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed and/or Refractory Multiple Myeloma

Start date: 2023-10-26
Primary completion: 2026-11-30
Enrollment: 83

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.